Success Metrics

Clinical Success Rate
73.9%

Based on 17 completed trials

Completion Rate
74%(17/23)
Active Trials
17(33%)
Results Posted
29%(5 trials)
Terminated
6(12%)

Phase Distribution

Ph not_applicable
9
18%
Ph phase_3
10
20%
Ph phase_1
3
6%
Ph phase_2
14
27%

Phase Distribution

3

Early Stage

14

Mid Stage

10

Late Stage

Phase Distribution36 total trials
Phase 1Safety & dosage
3(8.3%)
Phase 2Efficacy & side effects
14(38.9%)
Phase 3Large-scale testing
10(27.8%)
N/ANon-phased studies
9(25.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

70.8%

17 of 24 finished

Non-Completion Rate

29.2%

7 ended early

Currently Active

17

trials recruiting

Total Trials

51

all time

Status Distribution
Active(21)
Completed(17)
Terminated(7)
Other(6)

Detailed Status

Completed17
Recruiting12
unknown6
Terminated6
Active, not recruiting5
Not yet recruiting3

Development Timeline

Analytics

Development Status

Total Trials
51
Active
17
Success Rate
73.9%
Most Advanced
Phase 3

Trials by Phase

Phase 13 (8.3%)
Phase 214 (38.9%)
Phase 310 (27.8%)
N/A9 (25.0%)

Trials by Status

enrolling_by_invitation12%
unknown612%
not_yet_recruiting36%
active_not_recruiting510%
completed1733%
terminated612%
withdrawn12%
recruiting1224%

Recent Activity

Clinical Trials (51)

Showing 20 of 51 trialsScroll for more
NCT07567716

Infiltration Pattern of Locally Advanced ESCC

Enrolling By Invitation
NCT05357846Phase 3

PD-1 Inhibitor Combined With Neoadjuvant Chemoradiotherapy Plus Surgery for Locally Advanced ESCC (NEOCRTEC2101)

Recruiting
NCT07244978Phase 2

Neoadjuvant Ivonescimab(AK112) Combined With Chemotherapy in Patients With Resectable Esophageal Squamous Cell Carcinoma

Not Yet Recruiting
NCT07312526

Shanghai Clinical Cohort - Esophageal Cancer

Completed
NCT03740542Not Applicable

Pyloroplasty Versus No Pyloroplasty in Patients Undergoing Esophagectomy

Active Not Recruiting
NCT07505186Phase 2

Camrelizumab, Chemotherapy and Ivarmacitinib in Patients With Resectable Esophageal Squamous Cell Carcinoma

Not Yet Recruiting
NCT05706558

Retrospective Review of Esophageal Cancer at MSKCC

Recruiting
NCT07449208

Registry Study of People Who Are Having an Esophagectomy and Are at High Risk of Anastomotic Leak

Recruiting
NCT03801876Phase 3

Comparing Proton Therapy to Photon Radiation Therapy for Esophageal Cancer

Recruiting
NCT07317609Phase 1

Neoadjuvant Immunotherapy Combined With Chemotherapy Sequenced With Endoscopic Resection for Esophageal Cancer (Endosurgery-02)

Recruiting
NCT05659251Phase 2

Serplulimab Combined With Chemotherapy in Patients With Resectable Esophageal Squamous Cell Carcinoma

Active Not Recruiting
NCT06576973Phase 2

Adbelimumab Combined With Chemotherapy and Apatinib in Patients With Resectable Esophageal Squamous Cell Carcinoma

Recruiting
NCT04666090Phase 2

Carrelizumab, Chemotherapy and Apatinib in the Neoadjuvant Treatment of Resectable Esophageal Squamous Cell Carcinoma

Active Not Recruiting
NCT04460352Phase 3

Chemoradiotherapy Followed by Planned Surgery or by Surveillance and Surgery Only When Needed for Oesophageal Cancer

Recruiting
NCT02634645

TREAT-BE Study (Treatment With Resection and Endoscopic Ablation Techniques for Barrett's Esophagus)

Recruiting
NCT05950438

Investigating Outcomes of Elective Robotic Transhiatal Esophagectomy

Recruiting
NCT03306901Not Applicable

Chemoradiotherapy Versus Esophagectomy After Endoscopic Resection for Superficial Esophageal Squamous Cell Carcinoma

Active Not Recruiting
NCT06256185Not Applicable

Machine Learning to Predict Lymph Node Metastasis in T1 Esophageal Squamous Cell Carcinoma

Completed
NCT06060106

Endoscopic Submucosal Dissection Versus Esophagectomy for Early Esophageal Carcinoma

Completed
NCT01047111Not Applicable

Esophagectomy: Sweet Versus Ivor-Lewis (ESVIL) (ECTOP-2001)

Completed

Drug Details

Intervention Type
PROCEDURE
Total Trials
51